Option chain shows key data for KBC Groupe's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for KBC Groupe.

KBC Groupe (OTC:KBCSY) Stock, Option Chain

KBC Groupe

KBC Group

KBC was formed in 1998 by the merger of Belgian commercial bank Kredietbank, cooperative farmers bank CERA Bank, and cooperative insurer ABB Verzekering. KBC offers banking, insurance, and investment products. Belgium and the Czech Republic account for the most of KBC's profits, while the bank has smaller operations in Hungary, Slovakia, and Bulgaria.

Earnings

Large Cap

News

Upgrades

Markets

Analyst Ratings

Trading Ideas

KBCSY

KBC Group SA (OTC: KBCSY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.

KBC Group Upgraded to Buy: Here&#39;s What You Should Know

Intraday Update

Movers

AAXN

ACEL

ADBE

ADCOF

AEHR

AIQUY

AJRD

ALSWF

AMAT

AMRC

AMXEF

ANSS

APEMY

ARCAY

ARCVF

ARES

ARNC

ASMLF

ASTE

AVLR

AVXL

BAESY

BCLI

BESIY

BFAM

BILI

BILL

BRLXF

BTAI

BWXT

BXMT

CALX

CCYC

CDNS

CNSWF

CRMT

CTAS

CYTK

DAVA

DOCU

DOOO

DRUNF

ENTG

EQIX

ESPR

EXLS

EXPGF

EXPO

FAST

FCPT

FLIR

FZRO

GASE

GLIBA

GNRC

GRRB

HENC

HIMX

Hannover Ruckversicherungs Registered shares 

HVRRY

ICAD

Stocks That Hit 52-Week Highs On Thursday

ACGL

ACLS

ACRE

AGNC

Allianz Ag Muenchen Namen-Akt Vinkuliert Shares

ALIZF

ALLT

ALLVF

ALNY

ALPMY

ALSK

AMED

APAM

AQUA

ARMZF

ASHTF

ASHTY

ASML

ASND

ASPU

BAYZF

BCPC

CBRE

CBSH

CCMP

CCOI

CCXI

CGEN

CIFAF

CLBK

CLPBY

CSLLY

CTVEF

CWEN

CWEN-A

DKILY

DQJCY

DSDVY

DSNKY

ENPH

EONGY

EPRT

Eaton Vance Tax-Advantaged Global Dividend

FBHS

FELE

Flaherty Crumrine/Claymore Preferred Securities

KBC Groupe NV

KBC Group (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KBCSY#OTC">KBCSY</a>) reported quarterly earnings of $1.18 per share. This is a 4.42 percent increase over earnings of $1.13 per share from the same period last year. The company reported $3.06 billion in sales this quarter. This is a 3.65 percent increase over sales of $2.96 billion the same period last year.

KBC Group Q3 EPS $1.18 Up From $1.13 YoY, Sales $3.06B Up From $2.96B YoY

KBC Group SA (OTC: <a class="ticker" href="https://www.benzinga.com/stock/kbcsy#OTC">KBCSY</a>) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
The sole determinant of the Zacks rating is a company&#39;s changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
As such, the Zacks rating upgrade for KBC Group is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
<h2>Most Powerful Force Impacting Stock Prices</h2>
The change in a company&#39;s future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That&#39;s partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company&#39;s shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
For KBC Group, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company&#39;s underlying business. And investors&#39; appreciation of this improving business trend should push the stock higher.
<h2>Harnessing the Power of Earnings Estimate Revisions</h2>
As empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988.
<h2>Earnings Estimate Revisions for KBC Group</h2>
This company is expected to earn $5.93 per share for the fiscal year ending December 2024, which represents a year-over-year change of 36.3%.
Analysts have been steadily raising their estimates for KBC Group. Over the past three months, the Zacks Consensus Estimate for the company has increased 4%.
<h2>Bottom Line</h2>
Unlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of &#39;buy&#39; and &#39;sell&#39; ratings for its entire universe of more than 4000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a &#39;Strong Buy&#39; rating and the next 15% get a &#39;Buy&#39; rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
The upgrade of KBC Group to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
<a href="https://www.zacks.com/stock/news/2340047/kbc-group-kbcsy-upgraded-to-buy-here-s-what-you-should-know?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2340047">To read this article on Zacks.com click here.</a>

KBC Group Upgraded to Buy: Here's What You Should Know

KBC (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KBCSY#OTC">KBCSY</a>) is set to give its latest quarterly earnings report on Thursday, 2023-02-09. Here's what investors need to know before the announcement.
Analysts estimate that KBC will report an earnings per share (EPS) of $1.01. 
KBC bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.16, which was followed by a 2.03% increase in the share price the next day.
Here's a look at KBC's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2022</th>
<th>Q2 2022</th>
<th>Q1 2022</th>
<th>Q4 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.76</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.92</td>
<td>1.02</td>
<td>0.6</td>
<td>0.89</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.03%</td>
<td>0.48%</td>
<td>0.67%</td>
<td>-2.44%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of KBC were trading at $36.645 as of February 07. Over the last 52-week period, shares are down 18.51%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/KBCSY/earnings">To track all earnings releases for KBC visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KBC's Earnings: A Preview

&nbsp;
<h2>Upgrades</h2>
<ul>
<li>Barrington Research upgraded the previous rating for Dentsply Sirona Inc (NASDAQ:<a class="ticker" href="/stock/XRAY#NASDAQ">XRAY</a>) from Market Perform to Outperform. Dentsply Sirona earned $0.87 in the fourth quarter, compared to $0.73 in the year-ago quarter. The stock has a 52-week-high of $60.78 and a 52-week-low of $31.57. At the end of the last trading period, Dentsply Sirona closed at $59.71.</li>
<li>BTIG upgraded the previous rating for TrueCar Inc (NASDAQ:<a class="ticker" href="/stock/TRUE#NASDAQ">TRUE</a>) from Neutral to Buy. For the fourth quarter, TrueCar had an EPS of $0.01, compared to year-ago quarter EPS of $0.01. At the moment, the stock has a 52-week-high of $6.47 and a 52-week-low of $1.98. TrueCar closed at $5.18 at the end of the last trading period.</li>
<li>For Zoom Video Communications Inc (NASDAQ:<a class="ticker" href="/stock/ZM#NASDAQ">ZM</a>), Piper Sandler upgraded the previous rating of Neutral to Overweight. For the fourth quarter, Zoom Video Communications had an EPS of $1.22, compared to year-ago quarter EPS of $0.15. At the moment, the stock has a 52-week-high of $588.84 and a 52-week-low of $97.37. Zoom Video Communications closed at $409.66 at the end of the last trading period.</li>
<li>CIBC upgraded the previous rating for Bank of Nova Scotia (NYSE:<a class="ticker" href="/stock/BNS#NYSE">BNS</a>) from Neutral to Outperformer. In the first quarter, Bank of Nova Scotia showed an EPS of $1.44, compared to $1.41 from the year-ago quarter. The stock has a 52-week-high of $61.35 and a 52-week-low of $31.94. At the end of the last trading period, Bank of Nova Scotia closed at $59.74.</li>
<li>According to BMO Capital, the prior rating for Extra Space Storage Inc (NYSE:<a class="ticker" href="/stock/EXR#NYSE">EXR</a>) was changed from Market Perform to Outperform. In the fourth quarter, Extra Space Storage showed an EPS of $1.48, compared to $1.27 from the year-ago quarter. The stock has a 52-week-high of $131.59 and a 52-week-low of $72.70. At the end of the last trading period, Extra Space Storage closed at $123.67.</li>
<li>Exane BNP Paribas upgraded the previous rating for Tenaris SA (NYSE:<a class="ticker" href="/stock/TS#NYSE">TS</a>) from Underperform to Neutral. Tenaris earned $0.18 in the fourth quarter, compared to $0.26 in the year-ago quarter. The current stock performance of Tenaris shows a 52-week-high of $21.97 and a 52-week-low of $8.86. Moreover, at the end of the last trading period, the closing price was at $21.55.</li>
<li>For Satsuma Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="/stock/STSA#NASDAQ">STSA</a>), Credit Suisse upgraded the previous rating of Underperform to Neutral. Satsuma Pharmaceuticals earned $0.69 in the third quarter, compared to $2.26 in the year-ago quarter. The stock has a 52-week-high of $36.10 and a 52-week-low of $3.50. At the end of the last trading period, Satsuma Pharmaceuticals closed at $6.51.</li>
<li>For Repay Holdings Corp (NASDAQ:<a class="ticker" href="/stock/RPAY#NASDAQ">RPAY</a>), Wells Fargo upgraded the previous rating of Equal-Weight to Overweight. Repay Holdings earned $0.17 in the fourth quarter, compared to $0.20 in the year-ago quarter. The current stock performance of Repay Holdings shows a 52-week-high of $28.42 and a 52-week-low of $10.69. Moreover, at the end of the last trading period, the closing price was at $22.63.</li>
<li>According to KeyBanc, the prior rating for Akamai Technologies Inc (NASDAQ:<a class="ticker" href="/stock/AKAM#NASDAQ">AKAM</a>) was changed from Sector Weight to Overweight. In the fourth quarter, Akamai Technologies showed an EPS of $1.33, compared to $1.23 from the year-ago quarter. At the moment, the stock has a 52-week-high of $124.91 and a 52-week-low of $75.18. Akamai Technologies closed at $95.94 at the end of the last trading period.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings upgrades.</a>
&nbsp;
<h2>Downgrades</h2>
<ul>
<li>According to Wedbush, the prior rating for Skyline Champion Corp (NYSE:<a class="ticker" href="/stock/SKY#NYSE">SKY</a>) was changed from Outperform to Neutral. In the third quarter, Skyline Champion showed an EPS of $0.38, compared to $0.32 from the year-ago quarter. The stock has a 52-week-high of $47.57 and a 52-week-low of $10.82. At the end of the last trading period, Skyline Champion closed at $46.86.</li>
<li>For ADT Inc (NYSE:<a class="ticker" href="/stock/ADT#NYSE">ADT</a>), Barclays downgraded the previous rating of Equal-Weight to Underweight. ADT earned $0.12 in the fourth quarter, compared to $0.03 in the year-ago quarter. The current stock performance of ADT shows a 52-week-high of $17.21 and a 52-week-low of $3.40. Moreover, at the end of the last trading period, the closing price was at $7.73.</li>
<li>For Inseego Corp (NASDAQ:<a class="ticker" href="/stock/INSG#NASDAQ">INSG</a>), Stifel downgraded the previous rating of Buy to Hold. In the fourth quarter, Inseego showed an EPS of $0.07, compared to $0.10 from the year-ago quarter. The stock has a 52-week-high of $21.93 and a 52-week-low of $3.91. At the end of the last trading period, Inseego closed at $15.03.</li>
<li>According to Raymond James, the prior rating for Switch Inc (NYSE:<a class="ticker" href="/stock/SWCH#NYSE">SWCH</a>) was changed from Strong Buy to Outperform. In the fourth quarter, Switch showed an EPS of $0.06, compared to $0.04 from the year-ago quarter. The current stock performance of Switch shows a 52-week-high of $19.99 and a 52-week-low of $10.30. Moreover, at the end of the last trading period, the closing price was at $17.69.</li>
<li>According to Needham, the prior rating for Applied Optoelectronics Inc (NASDAQ:<a class="ticker" href="/stock/AAOI#NASDAQ">AAOI</a>) was changed from Buy to Hold. Applied Optoelectronics earned $0.20 in the fourth quarter, compared to $0.18 in the year-ago quarter. At the moment, the stock has a 52-week-high of $17.57 and a 52-week-low of $5.00. Applied Optoelectronics closed at $9.02 at the end of the last trading period.</li>
<li>For Athenex Inc (NASDAQ:<a class="ticker" href="/stock/ATNX#NASDAQ">ATNX</a>), Truist Securities downgraded the previous rating of Buy to Hold. In the fourth quarter, Athenex showed an EPS of $0.53, compared to $0.28 from the year-ago quarter. At the moment, the stock has a 52-week-high of $15.24 and a 52-week-low of $5.24. Athenex closed at $5.46 at the end of the last trading period.</li>
<li>According to Jefferies, the prior rating for FibroGen Inc (NASDAQ:<a class="ticker" href="/stock/FGEN#NASDAQ">FGEN</a>) was changed from Buy to Hold. For the fourth quarter, FibroGen had an EPS of $0.64, compared to year-ago quarter EPS of $1.12. At the moment, the stock has a 52-week-high of $57.21 and a 52-week-low of $22.65. FibroGen closed at $50.53 at the end of the last trading period.</li>
<li>For Viatris Inc (NASDAQ:<a class="ticker" href="/stock/VTRS#NASDAQ">VTRS</a>), JP Morgan downgraded the previous rating of Overweight to Neutral. The current stock performance of Viatris shows a 52-week-high of $18.86 and a 52-week-low of $14.56. Moreover, at the end of the last trading period, the closing price was at $14.72.</li>
<li>JP Morgan downgraded the previous rating for Athenex Inc (NASDAQ:<a class="ticker" href="/stock/ATNX#NASDAQ">ATNX</a>) from Overweight to Neutral. For the fourth quarter, Athenex had an EPS of $0.53, compared to year-ago quarter EPS of $0.28. The current stock performance of Athenex shows a 52-week-high of $15.24 and a 52-week-low of $5.24. Moreover, at the end of the last trading period, the closing price was at $5.46.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings downgrades.</a>
<h2>Initiations</h2>
<ul>
<li>For Lucira Health Inc (NASDAQ:<a class="ticker" href="/stock/LHDX#NASDAQ">LHDX</a>), William Blair initiated coverage, by setting the current rating at Outperform. The stock has a 52-week-high of $37.98 and a 52-week-low of $18.27. At the end of the last trading period, Lucira Health closed at $19.39.</li>
<li>Stifel initiated coverage on Angion Biomedica Corp (NASDAQ:<a class="ticker" href="/stock/ANGN#NASDAQ">ANGN</a>) with a Buy rating. The price target for Angion Biomedica is set to $40.00. The stock has a 52-week-high of $26.30 and a 52-week-low of $16.00. At the end of the last trading period, Angion Biomedica closed at $19.92.</li>
<li>Benchmark initiated coverage on Clene Inc (NASDAQ:<a class="ticker" href="/stock/CLNN#NASDAQ">CLNN</a>) with a Buy rating. The price target for Clene is set to $25.00. The stock has a 52-week-high of $16.50 and a 52-week-low of $6.23. At the end of the last trading period, Clene closed at $13.58.</li>
<li>Guggenheim initiated coverage on Bolt Biotherapeutics Inc (NASDAQ:<a class="ticker" href="/stock/BOLT#NASDAQ">BOLT</a>) with a Buy rating. The price target for Bolt Biotherapeutics is set to $42.00. The stock has a 52-week-high of $35.88 and a 52-week-low of $22.63. At the end of the last trading period, Bolt Biotherapeutics closed at $30.00.</li>
<li>Morgan Stanley initiated coverage on MP Materials Corp (NYSE:<a class="ticker" href="/stock/MP#NYSE">MP</a>) with an Overweight rating. The price target for MP Materials is set to $57.00. At the moment, the stock has a 52-week-high of $49.43 and a 52-week-low of $15.45. MP Materials closed at $46.37 at the end of the last trading period.</li>
<li>With an Overweight rating, Morgan Stanley initiated coverage on Bolt Biotherapeutics Inc (NASDAQ:<a class="ticker" href="/stock/BOLT#NASDAQ">BOLT</a>). The price target seems to have been set at $45.00 for Bolt Biotherapeutics. The stock has a 52-week-high of $35.88 and a 52-week-low of $22.63. At the end of the last trading period, Bolt Biotherapeutics closed at $30.00.</li>
<li>With an Outperform rating, SVB Leerink initiated coverage on Pharvaris NV (NASDAQ:<a class="ticker" href="/stock/PHVS#NASDAQ">PHVS</a>). The price target seems to have been set at $50.00 for Pharvaris. The current stock performance of Pharvaris shows a 52-week-high of $42.86 and a 52-week-low of $23.06. Moreover, at the end of the last trading period, the closing price was at $39.23.</li>
<li>With a Neutral rating, Goldman Sachs initiated coverage on Immunocore Holdings PLC (NASDAQ:<a class="ticker" href="/stock/IMCR#NASDAQ">IMCR</a>). The price target seems to have been set at $40.00 for Immunocore Holdings. The current stock performance of Immunocore Holdings shows a 52-week-high of $61.99 and a 52-week-low of $39.02. Moreover, at the end of the last trading period, the closing price was at $49.05.</li>
<li>With an Overweight rating, Piper Sandler initiated coverage on AVITA Medical Inc (NASDAQ:<a class="ticker" href="/stock/RCEL#NASDAQ">RCEL</a>). The price target seems to have been set at $27.00 for AVITA Medical. AVITA Medical earned $0.26 in the second quarter. The current stock performance of AVITA Medical shows a 52-week-high of $30.78 and a 52-week-low of $4.00. Moreover, at the end of the last trading period, the closing price was at $21.49.</li>
</ul>
<a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">See all analyst ratings initiations.</a>

Downgrades

Initiation

AAOI

AKAM

ANGN

ATNX

BHCCF

BOLT

CDMGF

CGJTF

CLNN

CRPLF

FGEN

HOYFF

IMCR

INSG

KRYAY

LHDX

PHVS

RCEL

REMYY

RPAY

STSA

STWRY

SWCH

THNPF

TMSNY

TRUE

VTRS

XRAY

Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2021

Exane BNP Paribas analyst Guillaume Tiberghien downgrades KBC (OTC:<a class="ticker" href="/stock/KBCSY#OTC">KBCSY</a>) from Outperform to Neutral.

Comments

KBC Groupe

KBC Groupe (KBCSY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga